A diabeteses retinopathia új kezelési lehetösége A PPAR-α-agonista fenofibrát hatása

Translated title of the contribution: A new approach to the treatment of diabetic retinopathy - PPAR-α agonist activity of fenofibrate

Research output: Contribution to journalArticle

Abstract

Diabetic retinopathy (DR) is a leading cause of visual impairment worldwide. It affects nearly half of patients with diabetes and its severity increases with the progress of diabetes. Glycotoxicity, lipotoxicity and hypertension are the main risk factors for the development of DR. The control of glucose homeostasis and blood pressure are the main noninvasive approaches that might have a role in the treatment of this condition. On the basis of new studies, RAS inhibitors and fenofibrate are promising candidates that can be used to retard DR progression and/or induce its regression. Two large-scale studies (FIELD, ACCORD Eye) have demonstrated that fenofibrate therapy significantly reduces the need for laser treatment of DR. The efficiency of this therapy, which is independent of lipid changes, is primarily attributable to the PPAR-α agonist activity of fenofibrates. According to guidelines that discuss the new therapeutic approaches of DR, fibrate therapy is a promising new option for preventing the progression of DR.

Original languageHungarian
Pages (from-to)433-437
Number of pages5
JournalLege Artis Medicinae
Volume21
Issue number6-7
Publication statusPublished - Jun 2011

Fingerprint

Fenofibrate
Peroxisome Proliferator-Activated Receptors
Diabetic Retinopathy
Therapeutics
Fibric Acids
Vision Disorders
Lasers
Homeostasis
Guidelines
Blood Pressure
Hypertension
Lipids
Glucose

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A diabeteses retinopathia új kezelési lehetösége A PPAR-α-agonista fenofibrát hatása. / Császár, A.

In: Lege Artis Medicinae, Vol. 21, No. 6-7, 06.2011, p. 433-437.

Research output: Contribution to journalArticle

@article{ef57872ffbc34896a34b3d1252ce9593,
title = "A diabeteses retinopathia {\'u}j kezel{\'e}si lehet{\"o}s{\'e}ge A PPAR-α-agonista fenofibr{\'a}t hat{\'a}sa",
abstract = "Diabetic retinopathy (DR) is a leading cause of visual impairment worldwide. It affects nearly half of patients with diabetes and its severity increases with the progress of diabetes. Glycotoxicity, lipotoxicity and hypertension are the main risk factors for the development of DR. The control of glucose homeostasis and blood pressure are the main noninvasive approaches that might have a role in the treatment of this condition. On the basis of new studies, RAS inhibitors and fenofibrate are promising candidates that can be used to retard DR progression and/or induce its regression. Two large-scale studies (FIELD, ACCORD Eye) have demonstrated that fenofibrate therapy significantly reduces the need for laser treatment of DR. The efficiency of this therapy, which is independent of lipid changes, is primarily attributable to the PPAR-α agonist activity of fenofibrates. According to guidelines that discuss the new therapeutic approaches of DR, fibrate therapy is a promising new option for preventing the progression of DR.",
keywords = "Diabetes mellitus, Fenofibrate, Ppar-α agonist, Retinopathy",
author = "A. Cs{\'a}sz{\'a}r",
year = "2011",
month = "6",
language = "Hungarian",
volume = "21",
pages = "433--437",
journal = "Lege Artis Medicinae",
issn = "0866-4811",
publisher = "Literatura Medica Publishing House",
number = "6-7",

}

TY - JOUR

T1 - A diabeteses retinopathia új kezelési lehetösége A PPAR-α-agonista fenofibrát hatása

AU - Császár, A.

PY - 2011/6

Y1 - 2011/6

N2 - Diabetic retinopathy (DR) is a leading cause of visual impairment worldwide. It affects nearly half of patients with diabetes and its severity increases with the progress of diabetes. Glycotoxicity, lipotoxicity and hypertension are the main risk factors for the development of DR. The control of glucose homeostasis and blood pressure are the main noninvasive approaches that might have a role in the treatment of this condition. On the basis of new studies, RAS inhibitors and fenofibrate are promising candidates that can be used to retard DR progression and/or induce its regression. Two large-scale studies (FIELD, ACCORD Eye) have demonstrated that fenofibrate therapy significantly reduces the need for laser treatment of DR. The efficiency of this therapy, which is independent of lipid changes, is primarily attributable to the PPAR-α agonist activity of fenofibrates. According to guidelines that discuss the new therapeutic approaches of DR, fibrate therapy is a promising new option for preventing the progression of DR.

AB - Diabetic retinopathy (DR) is a leading cause of visual impairment worldwide. It affects nearly half of patients with diabetes and its severity increases with the progress of diabetes. Glycotoxicity, lipotoxicity and hypertension are the main risk factors for the development of DR. The control of glucose homeostasis and blood pressure are the main noninvasive approaches that might have a role in the treatment of this condition. On the basis of new studies, RAS inhibitors and fenofibrate are promising candidates that can be used to retard DR progression and/or induce its regression. Two large-scale studies (FIELD, ACCORD Eye) have demonstrated that fenofibrate therapy significantly reduces the need for laser treatment of DR. The efficiency of this therapy, which is independent of lipid changes, is primarily attributable to the PPAR-α agonist activity of fenofibrates. According to guidelines that discuss the new therapeutic approaches of DR, fibrate therapy is a promising new option for preventing the progression of DR.

KW - Diabetes mellitus

KW - Fenofibrate

KW - Ppar-α agonist

KW - Retinopathy

UR - http://www.scopus.com/inward/record.url?scp=79960764902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960764902&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:79960764902

VL - 21

SP - 433

EP - 437

JO - Lege Artis Medicinae

JF - Lege Artis Medicinae

SN - 0866-4811

IS - 6-7

ER -